Bluebird, Carlyle Group and Capital
Carlyle and SK Capital to take gene therapy firm bluebird bio private
The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, bluebird stockholders will receive $3 per share in cash.
The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...
A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out ...
Blue Bird Corporation is a compelling investment due to its focus on electric school buses and attractive stock valuation despite recent performance setbacks. Read more here.
Analysts at DA Davidson boosted their FY2025 EPS estimates for Blue Bird in a note issued to investors on Friday, February 7th. DA Davidson analyst M. Shlisky now anticipates that the company will ...
Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on Blue Bird (BLBD – Research Report) and Alibaba (BABA ...
Blue Bird (NASDAQ:BLBD) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of ...
KBC Group NV’s holdings in Blue Bird were worth $55,000 as of its most recent SEC filing. A number of other hedge funds have also recently bought and sold shares of BLBD.
MACON, Ga.--(BUSINESS WIRE)--Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, has appointed John Wyskiel to the position of President and CEO ...
BLBD remains volatile despite strong earnings, federal funding uncertainties, and revised EV sales guidance. Explore more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback